Sugi Predict

Sugi Predict / Compounds / SCHEMBL371653

SCHEMBL371653

SCHEMBL371653

COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5cccc(CN6CCOCC6)c5)CC4)cc3)c2cc1OC

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 14/20 0.70
▸ KDR P35968 5/20 0.70
▸ AURKB Q96GD4 5/20 0.66
▸ FLT3 P36888 3/20 0.66
▸ AXL P30530 8/20 0.64
▸ FLT1 P17948 4/20 0.64
▸ MERTK Q12866 4/20 0.64
▸ AURKA O14965 2/20 0.64
▸ RIPK2 O43353 2/20 0.64
▸ ABL1 P00519 2/20 0.64
▸ EGFR P00533 2/20 0.64
▸ ERBB2 P04626 2/20 0.64
▸ NTRK1 P04629 2/20 0.64
▸ LCK P06239 2/20 0.64
▸ LYN P07948 2/20 0.64
▸ RET P07949 2/20 0.64
▸ HCK P08631 2/20 0.64
▸ ADRA2A P08913 2/20 0.64
▸ KIT P10721 2/20 0.64
▸ BCR P11274 2/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29693426 1.00 MET (0.70) METKDRAURKBFLT3AXL
SCHEMBL24444695 0.97 MET (0.67) METKDRAURKBFLT3AXL
SCHEMBL371968 0.93 AURKB (0.69) METKDRAURKBFLT3AXL
SCHEMBL29693409 0.93 AURKB (0.69) METKDRAURKBFLT3AXL
SCHEMBL15338503 0.93 MET (0.61) METKDRAURKBFLT3AXL
SCHEMBL29693495 0.92 AURKB (0.68) METKDRAURKBFLT3AXL
SCHEMBL371990 0.92 AURKB (0.68) METKDRAURKBFLT3AXL
SCHEMBL5085641 0.89 AURKB (0.63) METKDRAURKBFLT3AXL
SCHEMBL371881 0.87 MET (0.69) METKDRAURKBFLT3AXL
SCHEMBL371878 0.86 AURKB (0.74) METKDRAURKBFLT3AXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 — — EP claimed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US claimed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 — — US claimed
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP claimed
EP-3329918-A2 C-MET MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2018-06-06 — — EP claimed
US-20170355678-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2017-12-14 — — US claimed
EP-2409704-B1 c-Met modulators and methods of use EXELIXIS INC (US) 2017-09-20 — — EP claimed
US-20160185725-A1 c-Met Modulators and Method of Use EXELIXIS, INC. 2016-06-30 — — US claimed
US-20150376133-A1 C-Met Modulators and Methods of Use EXELIXIS, INC. 2015-12-31 — — US claimed
US-20120022065-A1 C-Met Modulators and Method of Use EXELIXIS, INC. (US) 2012-01-26 — — US claimed
EP-2409704-A2 c-Met modulators and methods of use Exelixis Inc. (US) 2012-01-25 — — EP claimed
WO-2009017838-A2 COMBINATIONS OF JAK-2 INHIBITORS AND OTHER AGENTS EXELIXIS, INC. (US) 2009-02-05 — — WO claimed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US claimed
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 — — EP disclosed
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 — — EP disclosed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US disclosed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331860-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MET 3/4885KDR 4/4885AURKB 790/4885
US-20070054928-A1 c-Met modulators and methods of use FLT4, FLT1, MET MET 3/4885KDR 4/4885AURKB 790/4885
US-20120022065-A1 C-Met Modulators and Method of Use FLT4, MET, FLT1 MET 2/4885KDR 5/4885AURKB 559/4885
US-20150376133-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MET 3/4885KDR 4/4885AURKB 790/4885
US-20170355678-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MET 3/4885KDR 4/4885AURKB 790/4885
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE FLT4, FLT1, MET MET 3/4885KDR 4/4885AURKB 790/4885
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 MET 2/4885KDR 5/4885AURKB 559/4885
US-20160185725-A1 c-Met Modulators and Method of Use FLT4, MET, FLT1 MET 2/4885KDR 5/4885AURKB 559/4885
US-11124482-B2 C-met modulators and methods of use FLT4, FLT1, MET MET 3/4885KDR 4/4885AURKB 790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.